Alx oncology to participate in the cantor oncology, hematology & hemeonc conference

South san francisco, calif., sept. 21, 2022 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo) a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced that jaume pons, ph.d., founder, president and chief executive officer, will participate in a panel and investor meetings at the cantor oncology, hematology & hemeonc conference on wednesday, september 28 in new york.
ALXO Ratings Summary
ALXO Quant Ranking